Regenxbio
RGNX
Regenxbio (RGNX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.43
- EPS estimate
- $0.08
- EPS surprise
- +446.38%
- Revenue surprise
- +10.64%
- Revenue
- $108.0M
- Revenue estimate
- $97.6M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $0.08 | $0.43 | +446.38% | $108.0M | SEC |
| Q1 2026 | May 14, 2026 | −$1.34 | −$1.72 | −28.65% | $6.4M | SEC |
| Q4 2025 | Mar 5, 2026 | −$0.88 | −$1.30 | −48.52% | $30.3M | SEC |
| Q3 2025 | Nov 6, 2025 | −$1.28 | −$1.20 | +6.37% | $29.7M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.94 | −$1.38 | −47.14% | $21.4M | SEC |
| Q1 2025 | May 12, 2025 | $0.46 | $0.12 | −73.93% | $89.0M | SEC |
| Q4 2024 | Mar 13, 2025 | −$1.14 | −$1.01 | +11.48% | $21.2M | SEC |
| Q3 2024 | Nov 6, 2024 | −$1.12 | −$1.17 | −4.25% | $24.2M | SEC |
| Q2 2024 | Aug 1, 2024 | −$1.29 | −$1.05 | +18.70% | $22.3M | SEC |
| Q1 2024 | May 8, 2024 | −$1.26 | −$1.38 | −9.60% | $15.6M | SEC |
| Q4 2023 | Feb 27, 2024 | −$1.27 | −$1.43 | −12.57% | $22.2M | SEC |
| Q3 2023 | Nov 8, 2023 | −$1.46 | −$1.41 | +3.20% | $28.9M | SEC |
| Q2 2023 | Aug 2, 2023 | −$1.19 | −$1.66 | −39.90% | $20.0M | SEC |
| Q1 2023 | May 3, 2023 | −$1.42 | −$1.53 | −7.69% | $19.1M | SEC |
| Q4 2022 | Feb 28, 2023 | −$1.28 | −$1.38 | −7.60% | $31.3M | SEC |
| Q3 2022 | Nov 3, 2022 | −$1.47 | −$1.75 | −18.89% | $26.5M | SEC |
| Q2 2022 | Aug 3, 2022 | −$1.40 | −$1.58 | −12.46% | $32.6M | SEC |
| Q1 2022 | May 4, 2022 | −$1.54 | −$1.79 | −16.30% | $22.2M | SEC |
| Q4 2021 | Mar 1, 2022 | $7.69 | $6.67 | −13.29% | $398.7M | SEC |
| Q3 2021 | Nov 2, 2021 | −$1.03 | −$1.37 | −32.64% | $30.8M | SEC |
Quarterly revenue
Frequently asked questions
When did Regenxbio (RGNX) last report earnings?
Regenxbio last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did RGNX beat earnings estimates?
Yes. Regenxbio reported EPS of $0.43 for Q2 2026 against a $0.08 estimate — a 446.38% beat.
How much revenue did RGNX report last quarter?
Regenxbio reported $108.0M in revenue for Q2 2026, against a consensus estimate of $97.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.